Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 5/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17173790 | 1.00 | KDM4E (0.34) | KDM4EL3MBTL1ALPLEHMT2EHMT1 | |
| SCHEMBL14821861 | 1.00 | KDM4E (0.34) | KDM4EL3MBTL1ALPLEHMT2EHMT1 | |
| SCHEMBL12383241 | 0.96 | KDM4E (0.32) | KDM4EL3MBTL1ALPL | |
| SCHEMBL12347415 | 0.96 | KDM4E (0.32) | KDM4EL3MBTL1ALPL | |
| SCHEMBL12856841 | 0.95 | KDM4E (0.35) | KDM4EL3MBTL1ALPLALDH1A1 | |
| SCHEMBL31442874 | 0.95 | KDM4E (0.33) | KDM4EL3MBTL1ALPL | |
| SCHEMBL17919267 | 0.95 | KDM4E (0.33) | KDM4EL3MBTL1ALPL | |
| SCHEMBL22283218 | 0.94 | SLC6A2 (0.33) | KDM4EALPL | |
| SCHEMBL17486694 | 0.94 | KDM4E (0.32) | KDM4EALPL | |
| SCHEMBL31442900 | 0.94 | SLC6A2 (0.33) | KDM4EALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-12-31 | — | — | US | disclosed |
| EP-3470086-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-11-05 | — | — | US | disclosed |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20200306385-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-10-01 | — | — | US | disclosed |
| US-10780181-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| WO-2014057122-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | ADC THERAPEUTICS SÀRL (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057118-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | ADC THERAPEUTICS SARL (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-8501934-B2 | Pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8487092-B2 | Pyrrolobenzodiazepines | SPIROGEN DEVELOPMENTS SARL (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-2350098-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN SARL (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2318413-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| WO-2010043877-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010010347-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD79B, BCL6B, BCL6 | KDM4E 1391/4885L3MBTL1 959/4885ALPL 4508/4885 |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | KDM4E 1572/4885L3MBTL1 2380/4885ALPL 2016/4885 |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | KDM4E 2257/4885L3MBTL1 2042/4885ALPL 4711/4885 |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | GRIN2C, ZKSCAN2, ZRANB2 | KDM4E 1381/4885L3MBTL1 2519/4885ALPL 3167/4885 |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | KDM4E 1518/4885L3MBTL1 1952/4885ALPL 1184/4885 |
| US-10780181-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | KDM4E 1391/4885L3MBTL1 959/4885ALPL 4508/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | KDM4E 1391/4885L3MBTL1 959/4885ALPL 4508/4885 |
| US-20200306385-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | CD22, CD2, CD2BP2 | KDM4E 1572/4885L3MBTL1 2380/4885ALPL 2016/4885 |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | HCRTR2, HCRTR1, CBR3 | KDM4E 3339/4885L3MBTL1 2768/4885ALPL 4856/4885 |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD4, IL2 | KDM4E 2257/4885L3MBTL1 2042/4885ALPL 4711/4885 |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | KDM4E 2257/4885L3MBTL1 2042/4885ALPL 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.